التفاصيل البيبلوغرافية
| العنوان: |
Diabetic nephropathy - Complications and treatment. |
| بيانات النشر: |
Dove Medical Press Ltd New Zealand 2014-10-29 |
| تفاصيل مُضافة: |
Lim A.K.H. |
| نوع الوثيقة: |
Electronic Resource |
| مستخلص: |
Diabetic nephropathy is a significant cause of chronic kidney disease and end-stage renal failure globally. Much research has been conducted in both basic science and clinical therapeutics, which has enhanced understanding of the pathophysiology of diabetic nephropathy and expanded the potential therapies available. This review will examine the current concepts of diabetic nephropathy management in the context of some of the basic science and pathophysiology aspects relevant to the approaches taken in novel, investigative treatment strategies.Copyright © 2014 Lim. |
| مصطلحات الفهرس: |
diabetic nephropathy/di [Diagnosis], diabetic nephropathy/dt [Drug Therapy], diabetic nephropathy/ep [Epidemiology], diabetic nephropathy/et [Etiology], diabetic nephropathy/su [Surgery], diabetic nephropathy/th [Therapy], diet therapy, disease surveillance, drug effect, drug targeting, glycemic control, human, inflammation, intracellular signaling, kidney biopsy, kidney blood flow, kidney metabolism, kidney pancreas transplantation, lifestyle modification, medical history, molecular pathology, nonhuman, oxidative stress, risk factor, risk reduction, screening test, tea, treatment planning, aldose reductase inhibitor/dt [Drug Therapy], aldosterone antagonist/cb [Drug Combination], aldosterone antagonist/dt [Drug Therapy], aliskiren/dt [Drug Therapy], aminoguanidine/dt [Drug Therapy], angiotensin receptor antagonist/cb [Drug Combination], angiotensin receptor antagonist/dt [Drug Therapy], atrasentan/dt [Drug Therapy], avosentan/dt [Drug Therapy], bardoxolone/dt [Drug Therapy], neutrophil gelatinase associated lipocalin/ec [Endogenous Compound], palosuran/dt [Drug Therapy], phosphodiesterase inhibitor/dt [Drug Therapy], pirfenidone/dt [Drug Therapy], pyridoxamine/dt [Drug Therapy], renin inhibitor/cb [Drug Combination], renin inhibitor/dt [Drug Therapy], sulodexide/dt [Drug Therapy], transforming growth factor beta1/ec [Endogenous Compound], unclassified drug, unindexed drug, vitamin D/dt [Drug Therapy], zinc, protein L FABP/ec [Endogenous Compound], vasculotropin/ec [Endogenous Compound], biological marker/ec [Endogenous Compound], calcium channel blocking agent/cb [Drug Combination], calcium channel blocking agent/dt [Drug Therapy], connective tissue growth factor/ec [Endogenous Compound], cystatin C/ec [Endogenous Compound], cytokine/ec [Endogenous Compound], dipeptidyl carboxypeptidase inhibitor/cb [Drug Combination], dipeptidyl carboxypeptidase inhibitor/dt [Drug Therapy], fish oil, hydroxymethylglutaryl coenzyme A reductase inhibitor/dt [Drug Therapy], kidney injury molecule 1/ec [Endogenous Compound], alternative medicine, article, Article |
| URL: |
https://repository.monashhealth.org/monashhealthjspui/handle/1/41642Test
International Journal of Nephrology and Renovascular Disease
Click here for full text options
LibKey Link |
| الإتاحة: |
Open access content. Open access content
Copyright 2016 Elsevier B.V., All rights reserved. |
| أرقام أخرى: |
AUSHL oai:repository.monashhealth.org:1/41642
International Journal of Nephrology and Renovascular Disease. 7 (pp 361-381), 2014. Date of Publication: 15 Oct 2014.
1178-7058 (electronic)
https://repository.monashhealth.org/monashhealthjspui/handle/1/41642Test
600156182
(Lim) Department of Nephrology, Monash Medical Center, Monash Health, Clayton, VIC, Australia (Lim) Department of General Medicine, Dandenong Hospital, Monash Health, Clayton, VIC, Australia (Lim) Department of Medicine, Monash University, Clayton, VIC, Australia
Lim A.K.H.; andy.lim@monash.edu
1305121315 |
| المصدر المساهم: |
MONASH HEALTH LIBRS
From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: |
edsoai.on1305121315 |
| قاعدة البيانات: |
OAIster |
